Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PharmiWeb

- PMLiVE

Medscape Education and Medics4RareDisease Uncover the Education Gaps in Their Compelling Rare Disease Day Campaign

Medscape Education and Medics4RareDisease are partnering on a Rare Disease Day awareness campaign. The campaign will form part of a series of short programs produced by ITN in collaboration with Genetic Alliance...

Medscape Education

- PMLiVE

Takeda’s dengue vaccine receives MHRA approval for those aged four years and older

Around 3.9 billion people globally are currently at risk of dengue, a mosquito-borne viral disease

- PMLiVE

Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis

More than ten million adults in the US alone over the age of 50 are estimated to have the condition

- PMLiVE

NHS urges people yet to receive their COVID-19 booster to come forward

Sunday 12 February is the last day people under 50 years of age who are not considered at risk can receive a booster

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

Biosimilars and beyond: innovating for improved patient outcomes

How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before

- PMLiVE

Gilead’s Trodelvy approved by FDA for metastatic breast cancer

HR+/HER2- is the most common type of breast cancer, accounting for 70% of new cases

- PMLiVE

World Health Organization releases new road map for breast cancer

Nearly 80% of breast and cervical cancer deaths occur in low- and middle-income countries

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide

- PMLiVE

Making new year resolutions that can also benefit others

Consider resolutions that could make 2023 a better year for many

- PMLiVE

ICR calls for improved biomarker cancer tests to help personalise treatment

Each cancer has a unique pattern of biomarkers that can affect how effective treatments are

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links